Patents Assigned to GALECTO BIOTECH AB
-
Publication number: 20190117627Abstract: The present invention relates to a polymorph of a compound of formula (I) This polymorph is particularly suitable in treating IPF by pulmonary administration.Type: ApplicationFiled: November 28, 2018Publication date: April 25, 2019Applicant: GALECTO BIOTECH ABInventors: Lise GRAVELLE, Anders PEDERSEN
-
Patent number: 10253059Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.Type: GrantFiled: July 6, 2015Date of Patent: April 9, 2019Assignee: GALECTO BIOTECH ABInventors: Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
-
Publication number: 20180369208Abstract: The present invention relates to a polymorph of a compound of formula (I) This polymorph is particularly suitable in treating IPF by pulmonary administration.Type: ApplicationFiled: December 16, 2016Publication date: December 27, 2018Applicant: GALECTO BIOTECH ABInventors: Lise GRAVELLE, Anders PEDERSEN
-
Publication number: 20180327440Abstract: The present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.Type: ApplicationFiled: November 8, 2016Publication date: November 15, 2018Applicant: GALECTO BIOTECH ABInventors: Fredrik ZETTERBERG, Ulf NILSSON, Hakon LEFFLER, Anders PEDERSEN, Hans SCHAMBYE, Thomas BRIMERT, Richard JOHNSSON
-
Publication number: 20180133240Abstract: The present invention relates to a compound of formula (I) for use in a method for treatment of pulmonary fibrosis in a human including administering once-a-day to the narrowest parts of the lung tissue of the human an amount of the compound of formula (I) effective to treat said pulmonary fibrosis.Type: ApplicationFiled: May 12, 2015Publication date: May 17, 2018Applicant: Galecto Biotech ABInventors: Hans SCHAMBYE, Anders PEDERSEN, Paul FORD
-
Publication number: 20170349619Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.Type: ApplicationFiled: January 28, 2016Publication date: December 7, 2017Applicant: Galecto Biotech ABInventors: Thomas BRIMERT, Richard JOHNSSON, Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
-
Publication number: 20170349622Abstract: The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.Type: ApplicationFiled: July 6, 2015Publication date: December 7, 2017Applicant: GALECTO BIOTECH ABInventors: Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
-
Publication number: 20170334940Abstract: An Embodiment of the invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.Type: ApplicationFiled: January 14, 2016Publication date: November 23, 2017Applicant: Galecto Biotech ABInventors: Fredrik ZETTERBERG, Ulf NILSSON, Hakon LEFFLER, Thomas BRIMERT, Richard JOHNSSON, Priya VERMA
-
Publication number: 20170275326Abstract: Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.Type: ApplicationFiled: June 2, 2017Publication date: September 28, 2017Applicant: GALECTO BIOTECH ABInventors: Neil Henderson, Tariq Sethi, Alison Mackinnon, Hakon Leffler, Ulf Nilsson
-
Patent number: 9688713Abstract: Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.Type: GrantFiled: December 11, 2015Date of Patent: June 27, 2017Assignee: Galecto Biotech ABInventors: Tariq Sethi, Alison Mackinnon, Hakon Leffler, Ulf Nilsson
-
Publication number: 20170095496Abstract: Provided is a method for treatment or prevention of ?-synucleinopathies in a mammalian subject, the method comprising administering a therapeutically effective amount of at least one composition to the subject, wherein the composition comprises a molecule for pharmacological modulation of galectin activity in a mammalian brain.Type: ApplicationFiled: April 8, 2015Publication date: April 6, 2017Applicant: GALECTO BIOTECH ABInventors: Tomas DEIERBORG, Antonio SERRANO, Hakon LEFFLER, Ulf NILSSON
-
Patent number: 9580456Abstract: The present invention relates to a compound of the general formula (I) for pulmonary administration. The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject.Type: GrantFiled: October 30, 2013Date of Patent: February 28, 2017Assignee: Galecto Biotech ABInventors: Ulf Nilsson, Hakon Leffler, Neil Henderson, Tariq Sethi, Alison MacKinnon
-
Patent number: 9353141Abstract: The present invention relates to novel compounds prepared from readily accessible 3-O-propargyl-D-galactopyranoside derivatives and having an effect as i.a., galectin inhibitors, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to ligands in a mammal, wherein said galectin is preferably a galectin-3. The novel compounds are defined by the general formula (I).Type: GrantFiled: January 24, 2013Date of Patent: May 31, 2016Assignee: Galecto Biotech ABInventors: Ulf Nilsson, Hakon Leffler, Balaram Mukhopadhyay, Vishal Rajput
-
Publication number: 20160096861Abstract: Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.Type: ApplicationFiled: December 11, 2015Publication date: April 7, 2016Applicant: GALECTO BIOTECH ABInventors: Tariq Sethi, Alison Mackinnon, Hakon Leffler, Ulf Nilsson
-
Patent number: 9243021Abstract: The present invention relates to a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method of monitoring development or progression of pulmonary fibrosis in a human subject, a method of monitoring or predicting exacerbation of symptoms in a human subject with pulmonary fibrosis as well as a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms.Type: GrantFiled: March 15, 2013Date of Patent: January 26, 2016Assignee: Galecto Biotech ABInventors: Tariq Sethi, Alison Mackinnon, Hakon Leffler, Ulf Nilsson
-
Publication number: 20150274764Abstract: The present invention relates to a compound of the general formula (I) for pulmonary administration. The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject.Type: ApplicationFiled: October 30, 2013Publication date: October 1, 2015Applicant: Galecto Biotech ABInventors: Ulf Nilsson, Hakon Leffler, Neil Henderson, Tariq Sethi, Alison MacKinnon
-
Publication number: 20140336146Abstract: The present invention relates to novel compounds prepared from readily accessible 3-O-propargyl-D-galactopyranoside derivatives and having an effect as i.a., galectin inhibitors, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to ligands in a mammal, wherein said galectin is preferably a galectin-3. The novel compounds are defined by the general formula (I).Type: ApplicationFiled: January 24, 2013Publication date: November 13, 2014Applicant: GALECTO BIOTECH ABInventors: Ulf Nilsson, Hakon Leffler, Balaram Mukhopadhyay, Vishal Rajput
-
Publication number: 20140200190Abstract: Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, wherein the galectin is preferably a galectin-3.Type: ApplicationFiled: March 17, 2014Publication date: July 17, 2014Applicant: Galecto Biotech ABInventors: Hakon LEFFLER, Ulf J. NILSSON, Henrik VON WACHENFELDT
-
Publication number: 20140171630Abstract: Novel synthesis routes for preparation of thiodigalactosides and intermediates are presented. The method includes the use of a 3-azido-galactosyl thiouronium salt derivative, which is activated to the corresponding thiol in situ, which in turn is directly reacted with a 3-azido-galactosyl bromide resulting in the 3,3?-di-azido-thio-di-galactoside before the thiol has a chance to reduce the azido 10 group. Hence, in situ formation of the 3-azido-galactosyl thiol from the thiouronium salt is essential in the synthesis procedure, because any other method that generate the thiol separately results in extensive unwanted azide reduction.Type: ApplicationFiled: February 20, 2014Publication date: June 19, 2014Applicant: GALECTO BIOTECH ABInventor: Ulf NILSSON
-
Patent number: 8703720Abstract: Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in the galectin is preferably a galectin-3.Type: GrantFiled: April 26, 2010Date of Patent: April 22, 2014Assignee: Galecto Biotech ABInventors: Hakon Leffler, Ulf J. Nilsson, Henrik Von Wachenfeldt